Note from Max Lataillade on LinkedIn in response to note

I do know that some folks don't like us contacting management, but Max L. made a nice comment on LinkedIn about the TNBC results, so I wrote and he replied. I wrote:

Quote:

---

Amazing results. Can you tell us how would these results affect the CRC trial just beginning with Leronlimab. Is it possible a similar MOA might take place there, even though CRCs don't usually greatly express PD-L1? Will they incorporate the possibility of adding a checkpoint inhibitor in that trial, depending on biomarkers?

---

Dr. Lataillade replied:

Quote:

---

Ken Chowder. Very good question Ken! As you pointed out, CRC is known to be a cold tumor, not much PD-L1 expression. We hope to see a similar impact on PD-L1 upregulation prospectively with Leronlimab, allowing patients potentially to benefit from ICIs. That option has been added in the CRC study. Best!

---